Bacterial Polysaccharide Vaccines: Glycoconjugates and Peptide-Mimetics

Microbial Glycobiology

Volumn , Issue , 2010, Pages 933-956

  Jennings, Harold J ^a   Pon, Robert A ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882853297     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374546-0.00048-1     Document Type: Chapter

References (109)

1. Alonso De Velasco E., Verheul A.F., Veeneman G.H., et al. Protein-conjugated synthetic di- and trisaccharides of pneumococcal type 17F exhibit a different immunogenicity and antigenicity than tetrasaccharide. Vaccine 1993, 11:1429-1436.
2. Alonso De Velasco E., Verheul A.F., van Steijn A.M.P., et al. Epitope specificity of rabbit immunoglobulin G (IgG) elicited by pneumococcal type 23F synthetic oligosaccharide- and native polysaccharide-protein conjugate vaccines: comparison with human anti-polysaccharide 23F IgG. Infect. Immun. 1994, 62:799-808.
3. Anderson P., Peter G., Johnston R.-B.J., Wetterlow L.H., Smith D.H. Immunization of humans with polyribophosphate, the capsular antigen of Hemophilus influenzae, type b. J. Clin. Invest. 1972, 51:39-44.
4. Anderson P.W., Pichichero M.E., Insel R.A., Betts R., Eby R., Smith D.H. Vaccines consisting of periodate-cleaved oligosaccharides from the capsule of Haemophilus influenzae type b coupled to a protein carrier: structural and temporal requirements for priming in the human infant. J. Immunol. 1986, 137:1181-1186.
5. Anderson P., Pichichero M., Edwards K., Porch C.R., Insel R. Priming and induction of Haemophilus influenzae type b capsular antibodies in early infancy by Dpo20, an oligosaccharide-protein conjugate vaccine. J. Pediatr. 1987, 111:644-650.
6. Anderson P.W., Pichichero M.E., Stein E.C., et al. Effect of oligosaccharide chain length, exposed terminal group, and hapten loading on the antibody response of human adults and infants to vaccines consisting of Haemophilus influenzae type b capsular antigen unterminally coupled to the diphtheria protein CRM197. J. Immunol. 1989, 142:2464-2468.
7. Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older. Recommendations of the immunization practices advisory committee (ACIP). MMWR Recomm. Rep. 1991, 40:1-7. Anon.
8. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-20032005. MMWR Morb. Mortal. Wkly. Rep. 2005, 54:893-897. Anon.
9. Anon, 2006a. Evaluation of the safety, immunogenicity, and compatibility with DTP of an investigational Vi-rEPA conjugate vaccine for typhoid fever when administered to infants in Vietnam concurrently with DTP. http://www.clinicaltrials.gov/ct2/show/nct00342628/.
10. Anon, 2006b. Salmonella typhi Vi O-acetyl pectin-rEPA conjugate vaccine. http://www.clinicaltrials.gov/ct2/show/NCT00277147/.
11. Anon, 2008. Novartis Menveo® vaccine shows superior immune response against four types of meningitis disease in pivotal phase III trial. http://www.novartis.com/newsroom/media-releases/en/2008/1216115.shtml/.
12. Baker C.J., Edwards M.S. Group B streptococcal conjugate vaccines. Arch. Dis. Child. 2003, 88:375-378.
13. Baker C.J., Kasper D.L. Group B streptococcal vaccines. Rev. Infect. Dis. 1985, 7:458-467.
14. Balmer P., Borrow R., Miller E. Impact of meningococcal C conjugate vaccine in the UK. J. Med. Microbiol. 2002, 51:717-722.
15. Bilukha O.O., Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm. Rep. 2005, 54:1-21.
16. Black S., Shinefield H., Fireman B., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J. 2000, 19:187-195.
17. Bogaert D., Veenhoven R.H., Ramdin R., et al. Pneumococcal conjugate vaccination does not induce a persisting mucosal IgA response in children with recurrent acute otitis media. Vaccine 2005, 23:2607-2613.
18. Brisson J.R., Uhrinova S., Woods R.J., et al. NMR and molecular dynamics studies of the conformational epitope of the type III group B Streptococcus capsular polysaccharide and derivatives. Biochemistry 1997, 36:3278-3292.
19. Bruge J., Bouveret-Le-Cam N., Danve B., Rougon G., Schulz D. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine 2004, 22:1087-1096.
20. Byington C.L., Samore M.H., Stoddard G.J., et al. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin. Infect. Dis. 2005, 41:21-29.
21. Chandran A., Watt J.P., Santosham M. Prevention of Haemophilus influenzae type b disease: past success and future challenges. Expert Rev. Vaccines 2005, 4:819-827.
22. Choo S., Seymour L., Morris R., et al. Immunogenicity and reactogenicity of a pneumococcal conjugate vaccine administered combined with a Haemophilus influenzae type B conjugate vaccine in United Kingdom infants. Pediatr. Infect. Dis. J. 2000, 19:854-862.
23. Claesson B.A., Schneerson R., Trollfors B., Lagergard T., Taranger J., Robbins J.B. Duration of serum antibodies elicited by Haemophilus influenzae type b capsular polysaccharide alone or conjugated to tetanus toxoid in 18- to 23-month-old children. J. Pediatr. 1990, 116:929-931.
24. Costantino P., Viti S., Podda A., Velmonte M.A., Nencioni L., Rappuoli R. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 1992, 10:691-698.
25. Crump J.A., Luby S.P., Mintz E.D. The global burden of typhoid fever. Bull. World Health Organ. 2004, 82:346-353.
26. Dagan R., Givon-Lavi N., Zamir O., Fraser D. Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers. Pediatr. Infect. Dis. J. 2003, 22:532-540.
27. Dagan R., Goldblatt D., Maleckar J.R., Yaich M., Eskola J. Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components. Infect. Immun. 2004, 72:5383-5391.
28. Eskola J., Kilpi T., Palmu A., et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 2001, 344:403-409.
29. Farrell D.J., Jenkins S.G., Reinert R.R. Global distribution of Streptococcus pneumoniae serotypes isolated from paediatric patients during 1999-2000 and the in vitro efficacy of telithromycin and comparators. J. Med. Microbiol. 2004, 53:1109-1117.
30. Finne J., Leinonen M., Mäkelä P.H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983, ii:355-357.
31. Fletcher M.A., Fritzell B. Brief review of the clinical effectiveness of PREVENAR against otitis media. Vaccine 2007, 25:2507-2512.
32. Francis T., Tillett W.S. Cutaneous reactions in pneumonia. The development of antibodies following the intradermal injection of type-specific polysaccharide. J. Exp. Med. 1930, 52:573-585.
33. Fraser A., Paul M., Goldberg E., Acosta C.J., Leibovici L. Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials. Vaccine 2007, 25:7848-7857.
34. Fusco P.C., Michon F., Tai J.Y., Blake M.S. Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates. J. Infect. Dis. 1997, 175:364-372.
35. Girard M.P., Preziosi M.P., Aguado M.T., Kieny M.P. A review of vaccine research and development: meningococcal disease. Vaccine 2006, 24:4692-4700.
36. Goebel W.F., Avery O.T. Chemo-immunological studies on conjugated carbohydrate-proteins. IV. The synthesis of p-aminobenzyl ether of the soluble specific substance of type III Pneumococcus and its coupling with protein. J. Exp. Med. 1931, 54:431-436.
37. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 1969, 129:1307-1326.
38. Gotschlich E.C., Goldschneider I., Lepow M.L., Gold R. The immune responses to bacterial polysaccharides in man. Antibodies in Human Diagnosis and Therapy 1977, 391-402. Raven Press, New York. E. Haber, R.M. Krause (Eds.).
39. Granoff D.M., Holmes S.J., Osterholm M.T., et al. Induction of immunologic memory in infants primed with Haemophilus influenzae type b conjugate vaccines. J. Infect. Dis. 1993, 168:663-671.
40. Gray S.J., Trotter C.L., Ramsay M.E., et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the meningococcal reference unit. J. Med. Microbiol. 2006, 55:887-896.
41. Grothaus M.C., Srivastava N., Smithson S.L., et al. Selection of an immunogenic peptide mimic of the capsular polysaccharide of Neisseria meningitidis serogroup A using a peptide display library. Vaccine 2000, 18:1253-1263.
42. Guttormsen H.K., Paoletti L.C., Mansfield K.G., Jachymek W., Jennings H.J., Kasper D.L. Rational chemical design of the carbohydrate in a glycoconjugate vaccine enhances IgM-to-IgG switching. Proc. Natl. Acad. Sci. USA 2008, 105:5903-5908.
43. Hammitt L.L., Bruden D.L., Butler J.C., et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J. Infect. Dis. 2006, 193:1487-1494.
44. Heyns K., Kiessling G., Lindenberg W., Paulsen H., Webster M.E. D-Galaktosaminuronsäure (2-Amino-2-desoxy-2-galakturonsäure) als Baustein des Vi-Antigens. Chem. Ber. 1959, 92:2435-2438.
45. Hoogerhout P., Evenberg D., van Boeckel C.A.A., et al. Synthesis of fragments of the capsular polysaccharide of Haemophilus influenzae type B, comprising two or three repeating units. Tetrahedron Lett. 1987, 28:1553-1556.
46. Hutchins W.A., Adkins A.R., Kieber-Emmons T., Westerink M.A. Molecular characterization of a monoclonal antibody produced in response to a group C meningococcal polysaccharide peptide mimic. Mol. Immunol. 1996, 33:503-510.
47. Hutchins W.A., Kieber-Emmons T., Carlone G.M., Westerink M.A. Human immune response to a peptide mimic of Neisseria meningitidis serogroup C in hu-PBMC-SCID mice. Hybridoma 1999, 18:121-129.
48. Insel R.A., Anderson P.W. Oligosaccharide-protein conjugate vaccines induce and prime for oligoclonal IgG antibody responses to the Haemophilus influenzae b capsular polysaccharide in human infants. J. Exp. Med. 1986, 163:262-269.
49. Jansen W.T.M., Hogenboom S., Thijssen M.J., et al. Synthetic 6B di-, tri-, and tetrasaccharide-protein conjugates contain Pneumococcal type 6A and 6B common and 6B- specific epitopes that elicit protective antibodies in mice. Infect. Immun. 2001, 69:787-793.
50. Jennings H.J. Polysaccharide vaccines against disease caused by Haemophilus influenzae, group B Streptococcus, and Salmonella typhi. Carbohydr. Eur. 1998, 21:17-23.
51. Jennings H.J., Lugowski C. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J. Immunol. 1981, 127:1011-1018.
52. Jennings H.J., Pon R.A. Polysaccharides and glycoconjugates as human vaccines. Polysaccharides in Medicinal Applications 1996, 473-479. Marcel Dekker, New York. S. Dimitriu (Ed.).
53. Jennings H.J., Sood R.K. Synthetic glycoconjugates as human vaccines. Neoglycoconjugates. Preparation and Applications 1994, 325-371. Academic Press, London. Y.C. Lee, R.T. Lee (Eds.).
54. Jennings H.J., Katzenellenbogen E., Lugowski C., Michon F., Roy R., Kasper D.L. Structure, conformation, and immunology of sialic acid-containing polysaccharides of human pathogenic bacteria. Pure Appl. Chem. 1984, 56:893-905.
55. Jennings H.J., Roy R., Gamian A. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J. Immunol. 1986, 137:1708-1713.
56. Jennings H.J., Gamian A., Ashton F.E. N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis. J. Exp. Med. 1987, 165:1207-1211.
57. Jessouroun, E., Da Silveira, I.A.F., Bastos, R.C., Frasch, C.E., Lee, C.J., 2005. Process for preparing polysaccharide-protein conjugate vaccines. Patent PCT/US2004/026431 [WO/2005/037320], 1-14. 2005. 8-6-2004.
58. Jodar L., Feavers I.M., Salisbury D., Granoff D.M. Development of vaccines against meningococcal disease. Lancet 2002, 359:1499-1508.
59. Kadirvelraj R., Gonzalez O.J., Foley B.L., et al. Understanding the bacterial polysaccharide antigenicity of Streptococcus agalactiae versus Streptococcus pneumoniae. Proc. Natl. Acad. Sci. USA 2006, 103:8149-8154.
60. Kieber-Emmons T., Ward R.E., Raychaudhuri S., Rein R., Kohler H. Rational design and application of idiotope vaccines. Int. Rev. Immunol. 1986, 1:1-26.
61. Kossaczka Z., Bystricky S., Bryla D.A., Shiloach J., Robbins J.B., Szu S.C. Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker. Infect. Immun. 1997, 65:2088-2093.
62. Kossaczka Z., Lin F.Y., Ho V.A., et al. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect. Immun. 1999, 67:5806-5810.
63. Laferriere C.A., Sood R.K., deMuys J.M., Michon F., Jennings H.J. Streptococcus pneumoniae type 14 polysaccharide-conjugate vaccines: length stabilization of opsonophagocytic conformational polysaccharide epitopes. Infect. Immun. 1998, 66:2441-2446.
64. Law M.R., Palomaki G., Alfirevic Z., et al. The prevention of neonatal group B streptococcal disease: a report by a working group of the Medical Screening Society. J. Med. Screen. 2005, 12:60-68.
65. Lefeber D.J., Kamerling J.P., Vliegenthart J.F.G. Synthesis of Streptococcus pneumoniae type 3 neoglycoproteins varying in oligosaccharide chain length, loading and carrier protein. Chem. Eur. J. 2001, 7:4411-4421.
66. Lesinski G.B., Smithson S.L., Srivastava N., Chen D., Widera G., Westerink M.A. A DNA vaccine encoding a peptide mimic of Streptococcus pneumoniae serotype 4 capsular polysaccharide induces specific anti-carbohydrate antibodies in Balb/c mice. Vaccine 2001, 19:1717-1726.
67. Lewis A.L., Nizet V., Varki A. Discovery and characterization of sialic acid O-acetylation in group B Streptococcus. Proc. Natl. Acad. Sci. USA1 2004, 01:11123-11128.
68. Lin F.Y., Ho V.A., Khiem H.B., et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N. Engl. J. Med. 2001, 344:1263-1269.
69. Mäkelä P.H., Peltola H., Kayhty H., Jousimies K., Pettay O. Polysaccharide vaccines of group A Neisseria meningitidis and Haemophilus influenzae type b: a field trial in Finland. J. Infect. Dis. 1977, 136(Suppl.):43-50.
70. Marburg S., Jorn D., Tolman R.L., et al. Bimolecular chemistry of macromolecules: synthesis of bacterial polysaccharide conjugates with Neisseria meningitidis membrane protein. J. Am. Chem. Soc. 1986, 108:5282-5287.
71. Mawas F., Niggemann J., Jones C., Corbel M.J., Kamerling J.P., Vliegenthart J.F.G. Immunogenicity in a mouse model of a conjugate vaccine made with a synthetic single repeating unit of type 14 pneumococcal polysaccharide coupled to CRM197. Infect. Immun. 2002, 70:5107-5114.
72. Melegaro A., Edmunds W.J. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur. J. Epidemiol. 2004, 19:353-363.
73. Michon F., Brisson J.R., Dell A., Kasper D.L., Jennings H.J. Multiantennary group-specific polysaccharide of group B Streptococcus. Biochemistry 1988, 27:5341-5351.
74. Michon F., Huang C.H., Farley E.K., Hronowski L., Di J., Fusco P.C. Structure activity studies on group C meningococcal polysaccharide-protein conjugate vaccines: effect of O-acetylation on the nature of the protective epitope. Dev. Biol. (Basel) 2000, 103:151-160.
75. Moe G.R., Tan S., Granoff D.M. Molecular mimetics of polysaccharide epitopes as vaccine candidates for prevention of Neisseria meningitidis serogroup B disease. FEMS Immunol. Med. Microbiol. 1999, 26:209-226.
76. Nilsson S., Bengtsson M., Norberg T. Solid-phase synthesis of a fragment of the capsular polysaccharide of Haemophilus Influenzae Type B using H-phosphonate intermediates. J. Carbohydr. Chem. 1992, 11:265-285.
77. Palmu A.A., Verho J., Jokinen J., Karma P., Kilpi T.M. The seven-valent pneumococcal conjugate vaccine reduces tympanostomy tube placement in children. Pediatr. Infect. Dis. J. 2004, 23:732-738.
78. Paoletti L.C., Wessels M.R., Rodewald A.K., Shroff A.A., Jennings H.J., Kasper D.L. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine. Infect. Immun. 1994, 62:3236-3243.
79. Peeters C.C., Evenberg D., Hoogerhout P., et al. Synthetic trimer and tetramer of 3-beta-d-ribose-(1-1)-d-ribitol-5-phosphate conjugated to protein induce antibody responses to Haemophilus influenzae type b capsular polysaccharide in mice and monkeys. Infect. Immun. 1992, 60:1826-1833.
80. Peltola H., Häyhty H., Sivonen A., Mäkelä P.H. Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double blind field study of 100,000 children 3 months to 5 years of age in Finland. Pediatrics 1977, 60:730-737.
81. Pincus S.H., Smith M.J., Jennings H.J., Burritt J.B., Glee P.M. Peptides that mimic the group B streptococcal type III capsular polysaccharide antigen. J. Immunol. 1998, 160:293-298.
82. Pozsgay V. Oligosaccharide-protein conjugates as vaccine candidates against bacteria. Adv. Carbohydr. Chem. Biochem. 2001, 56:153-199.
83. Prinz D.M., Smithson S.L., Kieber-Emmons T., Westerink M.A. Induction of a protective capsular polysaccharide antibody response to a multiepitope DNA vaccine encoding a peptide mimic of meningococcal serogroup C capsular polysaccharide. Immunology 2003, 110:242-249.
84. Prymula R., Peeters P., Chrobok V., et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006, 367:740-748.
85. Rennels M., King J.J., Ryall R., Papa T., Froeschle J. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr. Infect. Dis. J. 2004, 23:429-435.
86. Richmond P., Borrow R., Goldblatt D., et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J. Infect. Dis. 2001, 183:160-163.
87. Richmond P., Borrow R., Findlow J., et al. Evaluation of de-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and de-O-acetylated serogroup C strains. Infect. Immun. 2001, 69:2378-2382.
88. Robbins J.B. Vaccines for the prevention of encapsulated bacterial diseases: current status, problems and prospects for the future. Immunochemistry 1978, 15:839-854.
89. Robbins J.B., Austrian R., Lee C.J., et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J. Infect. Dis. 1983, 148:1136-1159.
90. Robbins J.B., Schneerson R., Szu S.C. Hypothesis: how licensed vaccines confer protective immunity. Novel Strategies in Design and Production of Vaccines 1996, 169-182. Plenum Press, New York. S. Cohet, A. Shafferman (Eds.).
91. Robbins J.B., Schneerson R., Gotschlich E.C. A rebuttal: epidemic and endemic meningococcal meningitis in sub-Saharan Africa can be prevented now by routine immunization with group A meningococcal capsular polysaccharide vaccine. Pediatr. Infect. Dis. J. 2000, 19:945-953.
92. Schneerson R., Barrera O., Sutton A., Robbins J.B. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J. Exp. Med. 1980, 152:361-376.
93. Scott D.A., Komjathy S.F., Hu B.T., et al. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 2007, 25:6164-6166.
94. Shin J.S., Lin J.S., Anderson P.W., Insel R.A., Nahm M.H. Monoclonal antibodies specific for Neisseria meningitidis group B polysaccharide and their peptide mimotopes. Infect. Immun. 2001, 69:3335-3342.
95. Snape M.D., Perrett K.P., Ford K.J., et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants - a randomized controlled trial. J. Am. Med. Assoc. 2008, 299:173-184.
96. Stein K.E. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J. Infect. Dis. 1992, 165(Suppl. 1):S49-S52.
97. Szu S.C., Li X.R., Stone A.L., Robbins J.B. Relation between structure and immunologic properties of the Vi capsular polysaccharide. Infect. Immun. 1991, 59:4555-4561.
98. Szu S.C., Bystricky S., Hinojosa-Ahumada M., Egan W., Robbins J.B. Synthesis and some immunologic properties of an O-acetyl pectin [poly(1→4)-α-d-GalpA]-protein conjugate as a vaccine for typhoid fever. Infect. Immun. 1994, 62:5545-5549.
99. Takala A.K., Eskola J., Leinonen M., et al. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with a Hib conjugate vaccine. J. Infect. Dis. 1991, 164:982-986.
100. Verez-Bencomo V., Fernandez-Santana V., Hardy E., et al. A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science 2004, 305:522-525.
101. Wang Y., Hollingsworth R.I., Kasper D.L. Ozonolysis for selectively depolymerizing polysaccharides containing β-aldosidic linkages. Proc. Natl. Acad. Sci. USA 1998, 95:6584-6589.
102. Wang Z.Y., Just G. Synthesis of fragments of the capsular polysaccharide of Haemophilus influenzae type B. Tetrahedron Lett. 1988, 29:1525-1528.
103. Ward J., Brenneman G., Letson G.W., Heyward W.L. Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group. N. Engl. J. Med. 1990, 323:1393-1401.
104. Weisser N.E., Almquist K.C., Hall J.C. A rAb screening method for improving the probability of identifying peptide mimotopes of carbohydrate antigens. Vaccine 2007, 25:4611-4622.
105. Wessels M.R., Munoz A., Kasper D.L. A model of high-affinity antibody binding to type III group B Streptococcus capsular polysaccharide. Proc. Natl. Acad. Sci. USA 1987, 84:9170-9174.
106. Westerink M.A.J., Giardina P.C. Anti-idiotype induced protection against Neisseria meningitidis serogroup C bacteremia. Microb. Path. 1992, 12:19-26.
107. Westerink M.A., Campagnari A.A., Wirth M.A., Apicella M.A. Development and characterization of an anti-idiotype antibody to the capsular polysaccharide of Neisseria meningitidis serogroup C. Infect. Immun. 1988, 56:1120-1127.
108. Westerink M.A.J., Giardina P.C., Apicella M.A., Kieber-Emmons T. Peptide mimicry of the meningococcal group c capsular polysaccharide. Proc. Natl. Acad. Sci. USA 1995, 92:4021-4025.
109. Zou W., Mackenzie R., Therien L., et al. Conformational epitope of the type III group B Streptococcus capsular polysaccharide. J. Immunol. 1999, 163:820-825.